G6PC1 and Hypoglycemia: Several gene replacement therapies based on viral vectors have shown promise in correcting hypoglycemia and preventing various complications in GSD1a animal models (10–14), among which an adeno-associated virus–based (AAV-based) product is currently being evaluated in clinical trials (e.g., ClinicalTrials.gov, NCT03517085).